Sanofi and GSK Launch Trial for COVID-19 Protein-Based Vaccine

French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments against the COVID-19 pandemic. Sanofi and GSK said on Thursday that they had started the 'Phase 1/2' trial for their adjuvanted COVID-19 vaccine, which they hope to make available across the world. This vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines with GSK's established pandemic adjuvant technology.